Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening
Drug Design, Development and Therapy · 2023
DOI: 10.2147/dddt.s389461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Julita Chlebowicz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, The University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Hypertension, WNK Lysine-Deficient Protein Kinase 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
WNK [with no lysine (K)] kinases are serine/threonine kinases associated with familial hyperkalemic hypertension (FHHt). WNKs are therapeutic targets for blood pressure regulation, stroke and several cancers including triple negative breast cancer and glioblastoma. Here, we searched for and characterized novel WNK kinase inhibitors.
Methods
We used a ~210,000-compound library in a high-throughput screen, re-acquisition and assay, commercial specificity screens and crystallography to identify WNK-isoform-selective inhibitors.
Results
We identified five classes of compounds that inhibit the kinase activity of WNK1: quinoline compounds, halo-sulfones, cyclopropane-containing thiazoles, piperazine-containing compounds, and nitrophenol-derived compounds. The compounds are strongly pan-WNK selective, inhibiting all four WNK isoforms. A class of quinoline compounds was identified that further shows selectivity among the WNK isoforms, being more potent toward WNK3 than WNK1. The crystal structure of the quinoline-derived SW120619 bound to the kinase domain of WNK3 reveals active site binding, and comparison to the WNK1 structure reveals the potential origin of isoform specificity.
Discussion
The newly discovered classes of compounds may be starting points for generating pharmacological tools and potential drugs treating hypertension and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
ORCID-Profile: Julita Chlebowicz, Radha Akella, John M Humphreys, Haixia He, Ashari R Kannangara, Shuguang Wei, Bruce Posner, Elizabeth J Goldsmith
Zitieren
APA
Chlebowicz, J., Akella, R., Humphreys, J. M., He, H., Kannangara, A. R., Wei, S., Posner, B., & Goldsmith, E. J. (2023). Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s389461
Vancouver
Chlebowicz J, Akella R, Humphreys JM, He H, Kannangara AR, Wei S, et al. Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s389461
BibTeX
@article{Chlebowicz2023,
author = {Chlebowicz, Julita and Akella, Radha and Humphreys, John M and He, Haixia and Kannangara, Ashari R and Wei, Shuguang and Posner, Bruce and Goldsmith, Elizabeth J},
title = {Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening},
journal = {Drug Design, Development and Therapy},
year = {2023},
doi = {10.2147/dddt.s389461}
}
EUVIMED